ABSTRACT OBJECTIVES This study sought to determine clinical, procedural, and treatment factors associated with acute stent thrombosis (AST) in the EUROMAX (European Ambulance Acute Coronary Syndrome Angiography) trial.
bleeding, and death at 30 days with a survival benefit that extended to 3 years (6,7). However, an absolute 1% excess of acute stent thrombosis (AST) was observed in the bivalirudin arm with the difference in ST rates between treatments no longer present at 30 days (1) . Since the HORIZONS-AMI trial was conducted, pPCI practice has evolved with increasing rates of prehospital diagnosis and initiation of treatment (8, 9) , use of radial access for catheterization (10) (11) (12) , and use of the novel oral P2Y 12 inhibitors ticagrelor and prasugrel, whereas routine use of GPI has been on the decline (13) (14) (15) (16) (17) . The EUROMAX (European Ambulance Acute Coronary Syndrome Angiography) trial was designed to test whether bivalirudin, initiated during transport for pPCI in STEMI patients, was superior to the use of heparin-based anticoagulation in the setting of contemporary practice (18) The protocol definition of non-CABG major bleeding has been previously published (18) . Bleeding events were also classified using TIMI and GUSTO Figures 1A and 1B, respectively. Values are n (%) or n/N (%). *These p values represent intracategory differences.
TIMI ¼ Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1 . 
DISCUSSION
In the EUROMAX trial, the overall incidence of AST was low (0.6%), but the risk was higher among patients randomized to bivalirudin. This is in keeping with similar observations from HORIZONS-AMI.
Although the absolute number of AST cases was small, thereby precluding the definitive assessment of associated factors, EUROMAX provided additional information on AST in the setting of contemporary Nykoebing, Denmark. E-mail: pc@docclemme.dk.
